Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080260 · ClinicalTrials.gov registry record · Phase 2
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02080260 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT02080260, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.
Interventions
- DRUG regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06-06 |
| Est. Completion | 2017-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080260
The ClinicalTrials.gov registry entry for NCT02080260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regorafenib is the first listed.
NCT02080260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02080260 about?
NCT02080260 is a clinical study titled "A Study of Regorafenib in Advanced Pancreatic Cancer Patients". This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperate...
What is the current status of trial NCT02080260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-06-06. Estimated completion is 2017-06-28.
What interventions are being tested in trial NCT02080260?
The interventions under investigation include: regorafenib (DRUG).
Who is sponsoring clinical trial NCT02080260?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.